(Approval lapsed) Bleomycin for Injection, USP 15 units per vial
Section 19A approved medicine
(Approval lapsed) Bleomycin for Injection, USP 15 units per vial
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN 20 605 457 430
Phone
1300 077 674
Approved until
Status
Expired
Medicines in short supply/unavailable
CIPLA BLEOMYCIN 15K bleomycin sulfate 15000 IU powder for injection vial - ARTG 220440
DBL BLEOMYCIN 15000IU (as sulfate) powder for injection vial - ARTG 42569
BLEO 15K bleomycin sulfate 15000 IU powder for injection vial - ARTG 157341
DBL BLEOMYCIN 15000IU (as sulfate) powder for injection vial - ARTG 42569
BLEO 15K bleomycin sulfate 15000 IU powder for injection vial - ARTG 157341
Indication(s)
Palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms:
- Squamous cell carcinoma of the skin, head and neck, and oesophagus (primary indication).
- Squamous cell carcinoma of the larynx, penis and uterine cervix.
- Squamous cell carcinoma of the bronchus (response infrequent).
- Choriocarcinoma and embryonal cell carcinoma of the testis.
- Advanced Hodgkin's disease and other lymphomas.
Note: Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.